Menopause as a distinct model of cutaneous ageing: Implications for advanced cosmetic testing
Menopause constitutes a specific biological model of skin ageing driven by the abrupt decline in oestrogen and its downstream effects on cutaneous homeostasis. This transition should not be interpreted as a simple acceleration of chronological ageing. Oestrogen depletion affects keratinocyte proliferation and differentiation, epidermal lipid synthesis, dermal extracellular matrix turnover and neurovascular regulation. Within the first five years post-menopause, up to 30% of dermal collagen may be lost, accompanied by measurable reductions in skin thickness and elasticity.
Clinically, these molecular changes translate into increased transepidermal water loss (TEWL), delayed barrier recovery, reduced dermal density, heightened neurosensory reactivity and frequently diffuse hair thinning. Such features justify dedicated evaluation strategies rather than extrapolation from conventional anti-ageing protocols.
Hydration claims in menopausal skin require more than single time-point corneometry. Dynamic TEWL measurements following a controlled barrier challenge, assessment of recovery kinetics and high-resolution imaging of epidermal thickness provide more discriminating endpoints. At molecular level, evaluation of markers such as filaggrin, aquaporin-3 and key enzymes involved in ceramide biosynthesis strengthens mechanistic substantiation and enhances claim robustness.
Loss of firmness represents another hallmark of the menopausal transition. Instrumental biomechanical assessments (e.g. cutometry or torsion analysis) gain significance when interpreted alongside structural imaging and biomarkers linked to collagen synthesis, elastin organisation and matrix metalloproteinase regulation. This integrated approach allows products to be positioned as modulators of dermal matrix homeostasis within a clearly defined hormonal context.
Altered vascular and neurocutaneous responses, clinically expressed as flushing, erythema and increased sensitivity, further differentiate menopausal skin. Quantitative colourimetry, microcirculation imaging and validated sensory assessment tools are essential to substantiate soothing and redness-reducing claims. In parallel, hormone-related hair thinning demands robust phototrichogram analysis, fibre diameter measurements and, where relevant, exploration of follicular biomarkers to support scalp-targeted efficacy.
Beyond structural parameters, menopause encompasses a significant psycho-physiological dimension. Hormonal fluctuations influence sleep quality, mood stability and stress perception, factors that may modify product experience and adherence. While remaining within the cosmetic regulatory framework, integration of validated quality-of-life questionnaires and selected physiological indicators enables substantiation of claims related to comfort, confidence and overall well-being.
This paradigm contributes to the rise of precision-driven hormonal cosmetics. Effective product development requires stratified study populations, well-characterised hormonal status, and multicentric, multi-ethnic investigations reflecting the diversity of phototypes and lived experiences across global markets. Importantly, endocrine transitions are not exclusive to women; andropause-associated changes may similarly impact skin physiology and hair density, calling for adapted evaluation models.
In this evolving landscape, Eurofins Cosmetics & Personal Care supports brands through tailored, integrated testing strategies combining clinical, instrumental, molecular and behavioural endpoints. By translating hormonal science into robust, regulatory-compliant evidence, we enable the development of innovative cosmetic solutions aligned with the complex and diverse realities of hormonal skin transitions.